NCIt definition : A neutralizing human monoclonal antibody directed against the spike (S) protein of
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially
be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon
administration, beludavimab specifically targets and binds to an epitope on the SARS-CoV-2
S protein that is shared with SARS-CoV-1, thereby blocking viral attachment and entry
into human cells and may thereby neutralize SARS-CoV-2. Beludavimab may also enhance
virus-specific T-cell activity. Altogether, this may slow the progression of the disease
and accelerate recovery, and may potentially provide temporary protection against
infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2,
plays an essential role in the infection pathway of the SARS-CoV-2 virus.;
UNII : FM2MK5954W;
CAS number : 2423016-74-2;
Molecule name : GSK 4182137; VIR 7832; GSK-4182137; VIR-7832;
Semantic type(s)